Soliris

Soliris is the brand name for eculizumab, a humanized monoclonal antibody that inhibits the complement system’s protein C5, broadly known as a terminal complement inhibitor.

🧬 What Soliris Is Used For

Soliris is FDA-approved to treat several rare, serious conditions:

• Paroxysmal Nocturnal Hemoglobinuria (PNH): In adults (18 +) and children, it reduces destructive red blood cell breakdown (hemolysis), lowers anemia and clotting risks, and often decreases transfusion requirements .

• Atypical Hemolytic Uremic Syndrome (aHUS): In both adults and children (≥ ~5 kg), Soliris helps prevent thrombotic microangiopathy (small blood vessel clots) and reduces kidney and organ damage .

• Generalized Myasthenia Gravis (gMG): For adults and children aged ≥ 6 years who are AChR‑antibody positive, it alleviates muscle weakness and improves daily function .

• Neuromyelitis Optica Spectrum Disorder (NMOSD): Specifically for adults who are AQP4‑antibody positive to reduce relapses of optic neuritis and myelitis .

⚙️ How It Works

Soliris binds to complement protein C5, blocking its cleavage into C5a (inflammatory) and C5b (which forms a membrane attack complex, C5b‑9) .
By stopping terminal pathway activation, Soliris prevents immune‑mediated destruction of cells—such as red blood cells in PNH and blood‑vessel clots in aHUS, or neurological damage in NMOSD and gMG .

⚠️ Important Safety & Administration Notes

• Route & Dosing: Administered via intravenous infusion.

  • PNH: Weekly infusions first 5 weeks, then maintenance every 2 weeks.

  • NMOSD: 900 mg weekly for 4 doses, then 1200 mg every 2 weeks .

• Vaccination Required: Significantly increases risk of serious, potentially fatal meningococcal infections. Meningococcal vaccines (serogroups A, C, W, Y, and B) are required at least 2 weeks before starting (or as early as possible if treatment must begin sooner).

• Restricted Access Program: Soliris is available only under a REMS (Risk Evaluation and Mitigation Strategy) program due to infection risk .

• Common Side Effects: Headache, nasal congestion, back pain, nausea, diarrhea, hypertension, respiratory or urinary infections, and fever; severity and frequency vary with the underlying condition treated (Resource Link). 

💰 Cost & Biosimilars

• Pricing: Soliris is one of the most expensive drugs globally—annual costs can reach $500,000 per patient in the U.S.

• Biosimilars Available:

  • Bkemv (eculizumab‑aeeb) – FDA-approved May 2024 as the first interchangeable biosimilar; can treat PNH and aHUS .

  • Epysqli (eculizumab‑aagh) – Approved July 2024; similar indications but not interchangeable at pharmacy level . Resource Link

• Ongoing Legal Challenges: Alexion (AstraZeneca) is currently facing a class-action lawsuit filed April 2025, alleging misuse of the patent system to extend its monopoly and delay cheaper biosimilars, inflating payer costs by potentially $2 billion.

✅ In Summary

• Soliris (eculizumab) is a groundbreaking complement inhibitor treating ultra-rare, life‑threatening diseases: PNH, aHUS, gMG, and NMOSD.

• It works by blocking the complement cascade at protein C5, protecting cells from immune-mediated injury.

• While highly effective, usage requires careful precautions—particularly meningococcal vaccination, monitoring, and enrollment in specialized safety programs.

• Its extreme cost and patent-protected exclusivity have made it controversial; newer biosimilars are now emerging.

If you’re curious about how Soliris compares to Ultomiris (a longer‑acting successor), or want more details about one of its indications, I’d be glad to help.